Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.
Although our knowledge of the pathophysiology of schizophrenia has increased, treatments for this devastating illness remain inadequate. Here, we critically assess rodent models and behavioural end points used in schizophrenia drug discovery and discuss why these have not led to improved treatments. We provide a perspective on how new models, based on recent advances in the understanding of the genetics and neural circuitry underlying schizophrenia, can bridge the translational gap and lead to the development of more effective drugs. We conclude that previous serendipitous approaches should be replaced with rational strategies for drug discovery in integrated preclinical and clinical programmes. Validation of drug targets in disease-based models that are integrated with translationally relevant end point assessments will reduce the current attrition rate in schizophrenia drug discovery and ultimately lead to therapies that tackle the disease process.
Centre for Neuroscience, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK. j.a.pratt@strath.ac.uk
Judith
J
Pratt
Catherine
C
Winchester
Neil
N
Dawson
Brian
B
Morris
D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000737:chemistry; D004195:Disease Models, Animal; D055808:Drug Discovery / Q000379:methods / Q000639:trends*; D006801:Humans; D012377:Rodentia; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics; D057170:Translational Research, Biomedical / Q000379:methods / Q000639:trends*
D014150:Antipsychotic Agents